Contribution of Renal and Non‐Renal Clearance on Increased Total Clearance of Adalimumab in Glomerular Disease
dc.contributor.author | Roberts, Brittney V. | en_US |
dc.contributor.author | Susano, Isidro | en_US |
dc.contributor.author | Gipson, Debbie S. | en_US |
dc.contributor.author | Trachtman, Howard | en_US |
dc.contributor.author | Joy, Melanie S. | en_US |
dc.date.accessioned | 2013-09-04T17:18:41Z | |
dc.date.available | 2014-10-06T19:17:42Z | en_US |
dc.date.issued | 2013-09 | en_US |
dc.identifier.citation | Roberts, Brittney V.; Susano, Isidro; Gipson, Debbie S.; Trachtman, Howard; Joy, Melanie S. (2013). "Contribution of Renal and Non‐Renal Clearance on Increased Total Clearance of Adalimumab in Glomerular Disease." The Journal of Clinical Pharmacology 53(9): 919-924. <http://hdl.handle.net/2027.42/99679> | en_US |
dc.identifier.issn | 0091-2700 | en_US |
dc.identifier.issn | 1552-4604 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/99679 | |
dc.description.abstract | The contribution of renal and non‐renal clearance toward targeted concentrations and/or effects of therapeutic proteins in nephrotic patients are unknown. This study dissected the contribution of clearance pathways to adalimumab elimination in patients with focal segmental glomerulosclerosis (FSGS). Urine was collected from seven patients treated with adalimumab. Renal clearance (Cl R ) was measured and non‐renal clearance (Cl NR ) was calculated as the difference between total clearance and Cl R . Differences in cumulative amount in urine, Cl R , and Cl NR between study weeks 1 and 16 and relationships between proteinuria (protein:creatinine ratio (Up/c)), and Cl R and Cl NR were evaluated. Up to 13% of the adalimumab dose was lost in urine. Cl NR contributed more than Cl R to enhanced total clearance. There was a nonlinear relationship between Up/c and Cl R (R 2 0.7059); an increase in Cl R beginning at Up/c of 12 mg/mg [slope 1.755, (C.I. −7.825 to 11.34)]. There was a linear relationship between Up/c and Cl NR (R 2 0.5039); for every one unit increase in Up/c, Cl NR would increase by 3.5 mL/hr ( P = 0.01). Both Cl R and Cl NR contribute to enhanced total clearance of adalimumab in glomerular disease secondary to FSGS. Additional research is needed to identify mechanisms for the increased Cl NR pathways. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Pharmacokinetics | en_US |
dc.subject.other | Renal Clearance | en_US |
dc.subject.other | Focal Segmental Glomerulosclerosis | en_US |
dc.subject.other | Glomerulonephritis | en_US |
dc.subject.other | Non‐Renal Clearance | en_US |
dc.title | Contribution of Renal and Non‐Renal Clearance on Increased Total Clearance of Adalimumab in Glomerular Disease | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 23813330 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/99679/1/jcph121.pdf | |
dc.identifier.doi | 10.1002/jcph.121 | en_US |
dc.identifier.source | The Journal of Clinical Pharmacology | en_US |
dc.identifier.citedreference | Lu TY, Ng KP, Cambridge G, et al. A retrospective seven‐year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients. Arthritis Rheum. 2009; 61: 482 – 487. | en_US |
dc.identifier.citedreference | Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA‐associated vasculitis. N Engl J Med. 2010; 363: 221 – 232. | en_US |
dc.identifier.citedreference | Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti‐tumor necrosis factor‐alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. Clin Ther. 2003; 25: 1700 – 1721. | en_US |
dc.identifier.citedreference | Trachtman H, Vento S, Gipson D, et al. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: Study design. BMC Nephrol. 2011; 12: 8. | en_US |
dc.identifier.citedreference | Joy MS, Gipson DS, Powell L, et al. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (novel therapies for resistant FSGS) study group. Am J Kidney Dis. 2010; 55: 50 – 60. | en_US |
dc.identifier.citedreference | Le Berre L, Herve C, Buzelin F, Usal C, Soulillou JP, Dantal J. Renal macrophage activation and Th2 polarization precedes the development of nephrotic syndrome in Buffalo/Mna rats. Kidney Int. 2005; 68: 2079 – 2090. | en_US |
dc.identifier.citedreference | McCarthy ET, Sharma R, Sharma M, et al. TNF‐alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol. 1998; 9: 433 – 438. | en_US |
dc.identifier.citedreference | Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D. The MHC class I‐like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest. 2004; 113: 1328 – 1333. | en_US |
dc.identifier.citedreference | Zhou J, Pop LM, Ghetie V. Hypercatabolism of IgG in mice with lupus‐like syndrome. Lupus. 2005; 14: 458 – 466. | en_US |
dc.identifier.citedreference | Ellis D, Buffone GJ. Protein clearances and selectivity determinations in childhood nephrosis: A reappraisal. Clin Chem. 1981; 27: 1397 – 1400. | en_US |
dc.identifier.citedreference | Aringer M, Smolen JS. Efficacy and safety of TNF‐blocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf. 2008; 7: 411 – 419. | en_US |
dc.identifier.citedreference | Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: An open‐label study. Arthritis Rheum. 2004; 50: 3161 – 3169. | en_US |
dc.identifier.citedreference | Shah SB, Hanauer SB. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease. Rev Gastroenterol Disord. 2008; 8: 159 – 168. | en_US |
dc.identifier.citedreference | Brambell FW, Hemmings WA, Morris IG. A theoretical model of gamma‐globulin catabolism. Nature. 1964; 203: 1352 – 1354. | en_US |
dc.identifier.citedreference | Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I‐related receptor FcRn. Annu Rev Immunol. 2000; 18: 739 – 766. | en_US |
dc.identifier.citedreference | Haymann JP, Levraud JP, Bouet S, et al. Characterization and localization of the neonatal Fc receptor in adult human kidney. J Am Soc Nephrol. 2000; 11: 632 – 639. | en_US |
dc.identifier.citedreference | Christianson GJ, Brooks W, Vekasi S, et al. Beta 2‐microglobulin‐deficient mice are protected from hypergammaglobulinemia and have defective antibody responses because of increased IgG catabolism. J Immunol. 1997; 159: 4781 – 4792. | en_US |
dc.identifier.citedreference | Akilesh S, Huber TB, Wu H, et al. Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci USA. 2008; 105: 967 – 972. | en_US |
dc.identifier.citedreference | Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab, association with disease activity, treatment failure during long‐term follow‐up. JAMA. 2011; 305: 1460 – 1468. | en_US |
dc.identifier.citedreference | Lopez‐Olivo MA, Kallen MA, Ortiz Z, Skidmore B, Suarez‐Almazor ME. Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: A systematic review. Arthritis Rheum. 2008; 59: 1625 – 1638. | en_US |
dc.identifier.citedreference | Ruggenenti P, Cravedi P, Sghirlanzoni MC, et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol. 2008; 3: 1652 – 1659. | en_US |
dc.identifier.citedreference | Ravani P, Magnasco A, Edefonti A, et al. Short‐term effects of rituximab in children with steroid‐ and calcineurin‐dependent nephrotic syndrome: A randomized controlled trial. Clin J Am Soc Nephrol. 2011; 6: 1308 – 1315. | en_US |
dc.identifier.citedreference | Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int. 2008; 73: 117 – 125. | en_US |
dc.identifier.citedreference | Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: a 2‐year study. Clin J Am Soc Nephrol. 2010; 5: 2188 – 2198. | en_US |
dc.identifier.citedreference | Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012; 64: 1215 – 1226. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.